 This Phase 3 study is being conducted to evaluate the efficacy and safety of ZestraTM compared to a placebo oil in women diagnosed as having acquired mixed interestdesirearousalorgasm disorders with varying presentations of each component in conditions of home use in conjunction with sexual activities. The study is a randomized, placebo-controlled, double-blind, parallel design trial. After subject screening, there is an open-label, placebo run-in period of four weeks, followed by a double-blinded 12 week treatment period. This design is consistent with the Paris 2003 recommendations for female sexual dysfunction FSD clinical trials and the Food and Drug Administration FDA Guidance on Clinical Development of Products for the Treatment of Female Sexual Dysfunction although the duration of active treatment in this study is 12 weeks rather than the 6 months suggested by the FDA for Phase 3 studies. 